INTRODUCTION
Evinacumab, a monoclonal antibody targeting angiopoietin-like protein 3 (ANGPTL3), has emerged as a promising therapeutic option for severe dyslipidemias. We have conducted a systematic review to evaluate its efficacy across different clinical settings.
METHODS
This systematic review and meta-analysis wa...
W. Masson, Martín Lobo, Mara Mansur et al.· Advances in Therapy· 0 citations
Background: Inhibition of the proprotein convertase subtilisin/kexin type 9 (PCSK9) is a well-established therapeutic strategy for significantly reducing low-density lipoprotein cholesterol (LDL-C) levels. In recent years, new oral PCSK9 inhibitors have been developed, providing emerging evidence regarding their lipid-...
W. Masson, Martín Lobo, G. Giunta et al.· Revista Argentina de Cardiol...· 0 citations
Findings support reclassification of the novel apolipoprotein A5 (ApoA5) variant as likely pathogenic and enable differentiation from multifactorial chylomicronemia syndrome.
J. Gutiérrez, P. Castaño, Claudia Monsalve et al.· Archives of Endocrinology an...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.